# Naringenin-7-O-glucoside

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/naringenin-7-o-glucoside
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** prunin, naringenin 7-glucoside, naringenin-7-β-D-glucopyranoside, 7-O-β-D-glucopyranosylnaringenin, naringenin 7-O-β-D-glucoside

## Overview

Naringenin-7-O-glucoside is a flavonoid glycoside composed of the aglycone naringenin bound to a glucose moiety at the 7-hydroxyl position, found naturally in citrus fruits and certain herbs. Its proposed biological activity centers on [free radical scaveng](/ingredients/condition/antioxidant)ing and modulation of [inflammatory](/ingredients/condition/inflammation) signaling enzymes, though robust human evidence remains absent.

## Health Benefits

• Potential [antioxidant](/ingredients/condition/antioxidant) effects suggested by chemical structure (no clinical evidence available)
• Possible [anti-inflammatory](/ingredients/condition/inflammation) properties indicated by suppliers (no clinical studies found)
• No human clinical trials identified in the research dossier
• No meta-analyses available to confirm health benefits
• Evidence quality: Insufficient - only theoretical benefits based on molecular structure

## Mechanism of Action

Naringenin-7-O-glucoside is hydrolyzed in the gut by lactase-phlorizin hydrolase and cytosolic beta-glucosidases to release the active aglycone naringenin, which then inhibits cyclooxygenase-2 (COX-2) and suppresses NF-κB transcription factor activation, reducing downstream [pro-inflammatory cytokine](/ingredients/condition/inflammation) expression including TNF-α and IL-6. Naringenin also chelates transition metal ions and donates hydrogen atoms to neutralize [reactive oxygen species](/ingredients/condition/antioxidant), with its catechol-like B-ring contributing to superoxide dismutase-mimetic activity. Additionally, in vitro data suggest modulation of CYP1A2 and CYP3A4 enzyme activity, which may influence xenobiotic [metabolism](/ingredients/condition/weight-management).

## Clinical Summary

No published human clinical trials have specifically investigated naringenin-7-O-glucoside as an isolated compound, and no meta-analyses exist for this glycoside form. The available evidence is limited to in vitro cell culture studies and rodent models, where oral administration of structurally related naringenin at doses of 50–200 mg/kg body weight demonstrated [antioxidant](/ingredients/condition/antioxidant) and [hepatoprotective](/ingredients/condition/detox) effects in chemically induced injury models. Bioavailability studies in rats suggest the glucoside form has lower intestinal absorption compared to aglycone naringenin due to its dependence on intestinal glycosidase activity for conversion. The overall evidence level is preclinical and insufficient to support efficacy claims in humans.

## Nutritional Profile

Naringenin-7-O-glucoside (also known as prunin) is a flavanone glycoside with the molecular formula C₂₁H₂₂O₁₀ and a molecular weight of ~434.4 g/mol. It is not a macronutrient source and provides negligible calories, protein, fat, or fiber. As a bioactive compound, it is the 7-O-β-D-glucopyranoside of naringenin, found naturally in citrus fruits (grapefruit, oranges, lemons), tomatoes, and certain herbs. Typical concentrations in food sources are low, generally ranging from ~1–50 mg/kg fresh weight in citrus peel and juice, with grapefruit juice containing roughly 5–20 mg/L. Key bioactive characteristics: the glucoside moiety increases water solubility compared to its aglycone (naringenin) but reduces passive intestinal absorption. Oral bioavailability is limited; the compound requires hydrolysis by intestinal β-glucosidases and/or colonic microbiota to release free naringenin before significant absorption occurs. Naringenin (the aglycone) itself has an estimated oral bioavailability of only ~5–15% in animal models, with extensive first-pass hepatic [metabolism](/ingredients/condition/weight-management) via glucuronidation and sulfation (primarily UGT1A1, UGT1A9, SULT1A1 pathways). No significant vitamin or mineral content is associated with this isolated compound. It contains no essential amino acids, dietary fiber, or fatty acids. The compound possesses a flavanone backbone with two hydroxyl groups (positions 5 and 4') and one glycosylated hydroxyl (position 7), which are relevant to its theoretical radical-scavenging capacity, though glycosylation at the 7-position partially attenuates [antioxidant](/ingredients/condition/antioxidant) potency relative to free naringenin. Co-consumption with dietary fats or other food matrix components may modestly influence absorption kinetics, but quantitative human pharmacokinetic data specific to naringenin-7-O-glucoside remain sparse. Plasma concentrations of naringenin metabolites after typical dietary intake of citrus products are generally in the low nanomolar to low micromolar range (peak ~0.1–6 µM), with a Tmax of approximately 4–6 hours reflecting colonic metabolism of the glycoside.

## Dosage & Preparation

No clinically studied dosage ranges have been established for naringenin-7-O-glucoside. Commercial preparations are available at ≥98% purity, stored at -20°C. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

No formal toxicology or safety studies have been conducted specifically on naringenin-7-O-glucoside in humans, and no established tolerable upper intake level exists. Because the compound is metabolized to naringenin, potential inhibition of CYP3A4 and CYP1A2 enzymes may increase plasma concentrations of co-administered drugs such as statins, calcium channel blockers, and certain immunosuppressants, mirroring interactions documented for grapefruit-derived flavonoids. Individuals taking cyclosporine, felodipine, or anticoagulants like warfarin should exercise caution given theoretical pharmacokinetic interference. Safety during pregnancy and lactation has not been studied, and use is not recommended in these populations without medical supervision.

## Scientific Research

No human clinical trials, randomized controlled trials (RCTs), or meta-analyses specifically on naringenin-7-O-glucoside were identified in the available research. The research dossier contains no PubMed PMIDs or study details regarding clinical efficacy.

## Historical & Cultural Context

No historical or traditional medicinal uses are documented in the provided research. The compound has been identified in sour cherry and other plants but lacks documented traditional applications.

## Synergistic Combinations

Naringenin, quercetin, hesperidin, rutin, vitamin C

## Frequently Asked Questions

### What foods contain naringenin-7-O-glucoside naturally?

Naringenin-7-O-glucoside occurs naturally in citrus fruits, particularly grapefruit peel and juice, as well as in tomato skin and certain medicinal plants such as Drynaria fortunei. Concentrations in grapefruit peel extracts have been reported in the range of 0.1–2.5 mg/g dry weight depending on cultivar and ripeness. It is structurally related to but distinct from naringin, which carries a neohesperidose sugar rather than glucose.

### How is naringenin-7-O-glucoside different from naringenin?

Naringenin-7-O-glucoside is the glycosylated prodrug form of naringenin, with a glucose molecule attached at the 7-hydroxyl position that must be cleaved by intestinal glycosidases before absorption. This glycosidic bond generally reduces passive intestinal permeability relative to the free aglycone, meaning bioavailability of the glucoside is dependent on microbial and enzymatic hydrolysis in the gut. Once converted, the released naringenin exerts the same antioxidant and anti-inflammatory mechanisms attributed to the aglycone form.

### Does naringenin-7-O-glucoside interact with medications?

Because naringenin-7-O-glucoside is metabolized to naringenin, it carries theoretical potential to inhibit cytochrome P450 enzymes CYP3A4 and CYP1A2, which are responsible for metabolizing a broad range of pharmaceuticals including certain statins, benzodiazepines, and immunosuppressants. This is analogous to the well-documented drug interactions of grapefruit juice, which contains related flavonoids. Individuals on prescription medications should consult a healthcare provider before supplementing, as no direct drug interaction studies for this specific compound exist.

### Are there any human clinical trials on naringenin-7-O-glucoside?

As of the current research dossier, no human clinical trials have been published investigating naringenin-7-O-glucoside as an isolated ingredient, and no randomized controlled trials or meta-analyses are available to confirm its efficacy or optimal dosing. Existing evidence is restricted to in vitro assays and animal models, where related flavonoids have shown biological activity but at doses that do not directly translate to human supplementation guidance. This significant evidence gap means any purported health benefits remain speculative and unverified in clinical settings.

### What is the antioxidant mechanism of naringenin-7-O-glucoside?

After hydrolysis to naringenin, the compound exerts antioxidant effects primarily through direct hydrogen atom transfer to reactive oxygen species such as superoxide anion and hydroxyl radicals, leveraging its phenolic hydroxyl groups as electron donors. It also chelates redox-active metal ions including iron(II) and copper(II), preventing them from catalyzing Fenton-type reactions that generate highly destructive hydroxyl radicals. In cell-based models, naringenin has been shown to upregulate endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase via Nrf2/ARE pathway activation, adding an indirect antioxidant dimension.

### What is the bioavailability of naringenin-7-O-glucoside compared to other flavonoid glycosides?

Naringenin-7-O-glucoside is a glycosylated form of naringenin, which may affect its absorption and bioavailability in the digestive system. The glucose moiety attached to naringenin can influence how quickly it is metabolized and absorbed compared to aglycone forms. Limited research suggests that glycosylated flavonoids may have different intestinal transport mechanisms, but specific bioavailability data for naringenin-7-O-glucoside in humans is not well-documented.

### Are there safety concerns for specific populations considering naringenin-7-O-glucoside supplementation?

While naringenin-7-O-glucoside is derived from citrus sources generally recognized as safe for most populations, formal safety studies in pregnant women, nursing mothers, and young children have not been conducted. Individuals with citrus allergies or sensitivities should exercise caution. Since clinical trial data is limited, vulnerable populations should consult healthcare providers before supplementation.

### How strong is the current scientific evidence supporting health claims for naringenin-7-O-glucoside?

The evidence supporting naringenin-7-O-glucoside is currently insufficient, as no human clinical trials have been completed and available evidence is limited to in vitro and theoretical assessments based on its chemical structure. Manufacturers may suggest antioxidant or anti-inflammatory benefits based on preliminary research, but these claims lack clinical validation. More rigorous human studies are needed to substantiate any therapeutic benefits.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*